Hot Stocks To Buy For 2018

WASHINGTON The IRS strikes back: The tax agency reports that the number of identity theft victims plummeted last year after agents struggled for years to combat what has become a multibillion-dollar industry.

The number of victims dropped by 46 percent, to 376,000, the IRS said. These taxpayers had their identities stolen by criminals who used their Social Security numbers and birthdates to obtain fraudulent tax refunds.

The IRS stopped nearly 1 million fraudulent refunds from being issued last year. They totaled almost $6.6 billion, the agency said.

“It’s a much more challenging time for the cybercrooks,” said Mark Ciaramitaro, vice president for retail tax products and services at H&R Block. “All of the easy paths have been closed.”

Identity theft exploded from 2010 to 2012, and “for a time overwhelmed law enforcement and the IRS,” said John Dalrymple, deputy IRS commissioner for services and enforcement.

Hot Stocks To Buy For 2018: CASI Pharmaceuticals, Inc.(CASI)

Advisors’ Opinion:

  • [By Lisa Levin]

    CASI Pharmaceuticals Inc (NASDAQ: CASI) shares shot up 62 percent to $3.61 following disclosure company Director He Wei-Wu purchased 200,000 shares on October 5 and 6. The stock rallied 15 percent on no news during Tuesday's intraday session.

  • [By Jim Robertson]

    US based but China focused small cap biopharmaceutical stockCASI Pharmaceuticals (NASDAQ: CASI) is up around 78% over the last three trading days on no apparent news on the newswires as the following chart illustrates:

Hot Stocks To Buy For 2018: American Express Company(AXP)

Advisors’ Opinion:

  • [By ]

    2. Low Debt Levels
    By looking through his previous success stories like Coca-Cola (NYSE: KO), American Express (NYSE: AXP), and Wells Fargo (NYSE: WFC), it is clear that Buffett carefully examines a company’s balance sheet, and prefers to invest in those with relatively modest debt burdens.

  • [By Paul Ausick]

    GE shares have lost about 14.4% of their value in 2018 and have fallen almost 50% over the past 12 months. The second-worst Dow stock so far this year is Procter & Gamble Co. (NYSE: PG), down 13%, followed by Exxon Mobil Corp. (NYSE: XOM), down about 9.4%, then Chevron Corp. (NYSE: CVX), down about 9.3%, and American Express Co. (NYSE: AXP), down about 7.6%.

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded down 1.28% at $79.31. The stock’s 52-week range is $57.15 to $82.00. Volume was just above the daily average of around 4 million shares. The credit card issuer had no specific news.

  • [By Paul Ausick]

    American Express Co. (NYSE: AXP) traded down 1.32% at $75.25. The stock’s 52-week range is $50.27 to $76.55. Volume was about 40% below the daily average of around 4.7 million shares. The company traded had no specific news Thursday.

  • [By Demitrios Kalogeropoulos]

    As for individual stocks, American Express (NYSE:AXP) and CSX (NASDAQ:CSX)both beat the market following quarterly earnings news.

    Image source: Getty Images.

Hot Stocks To Buy For 2018: Identiv, Inc.(INVE)

Advisors’ Opinion:

  • [By Lisa Levin]

    The industries that are driving the market today are:

    Cement: This industry gained 3.4 percent by 2:30 pm. The top stock within the industry was Cemex SAB de CV (ADR) (NYSE: CX), which gained 4.7 percent. Cemex’s PEG ratio is 0.16.
    Computer Peripherals: This industry rose 2.6 percent by 2:30 pm ET. The top performer in this industry was Identiv Inc (NASDAQ: INVE), which gained 13.5 percent. Identiv shares have climbed 44.83 percent over the past 52 weeks, while the S&P 500 index has increased 8.61 percent in the same period.
    Internet Service Providers: The industry gained 2 percent by 2:30 pm. The top performer in this industry was TrueCar Inc (NASDAQ: TRUE) which gained 3.4 percent. TrueCar shares have jumped 60.90 percent over the past 52 weeks, while the S&P 500 index has increased 8.61 percent in the same period.
    Regional – Southwest Banks: This industry moved up 1.9 percent by 2:30 pm. The top performer in this industry was Veritex Holdings Inc (NASDAQ: VBTX), which rose 6.6 percent

Hot Stocks To Buy For 2018: Great Basin Scientific, Inc.(GBSN)

Advisors’ Opinion:

  • [By Lisa Levin]

    Great Basin Scientific Inc (NASDAQ: GBSN) shares dropped 18 percent to $0.92 on Q1 results. Great Basin Scientific posted Q1 net income of $21,503,600, versus a year-ago net loss of $33,652,500.

  • [By Paul Ausick]

    Great Basin Scientific Inc. (NASDAQ: GBSN) dropped about 15% on Thursday to post a new 52-week low of $2.90 after closing at $3.42 on Wednesday. The stock’s 52-week high is $45,024.00. Volume was more than 3 times the daily average of around 150,000 shares. The medical diagnostics company had no specific news Thursday. Since mid-March the company has split the stock twice: the first was a 1-for-35 split and the second a 1-for-80 split.

Hot Stocks To Buy For 2018: PPL Corporation(PPL)

Advisors’ Opinion:

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $32.48 after closing Monday at $33.97. The 52-week high is $40.20. Volume was about 5.9 million, nearly a third higher than the daily average of around 3.9 million shares. The electric utility company had no specific news.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $31.53 after closing Tuesday at $32.42. The 52-week high is $40.20. Volume was about 15.5 million, more than three times the daily average of around 4 million shares. The electric utility company took a downgrade on Tuesday and the fallout continues to drop.

  • [By Paul Ausick]

    PPL Corp. (NYSE: PPL) posted a 52-week low of $30.81 after closing Friday at $31.13. The 52-week high is $40.20. Volume was about 3.5 million, about 25% below the daily average of around 4.5 million shares. The electric utility company had no specific news.

Hot Stocks To Buy For 2018: The NeutriSci International (NU)

Advisors’ Opinion:

  • [By Matthew Briar]

    What do you get when you cross a science that drastically improves the absorption of cannabidiol (the healthy component of cannabis) with pterostilbene (an antioxidant) tablet? It’s not a joke in search of a punch line. It’s going to be the health supplement millions of consumers have been waiting for, brought to them by a joint venture between NeutriSci International Inc (CVE:NU) and Lexaria Bioscience Corp (OTCMKTS:LXRP). The two companies announced this morning they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line.

    Lexaria has developed and patented a technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity.

    Just to be clear, hemp and marijuana are not the same thing. Hemp doesn’t have any tetrahydrocannabinol (or THC) in it, which is the key driver of its psychoactive — the ‘high’ — response. Hemp, and hemp oil to be exact, does have cannabidiol in it though, and for those who’ve been following the saga of medical marijuana and cannabis, they’ll know cannabidiol can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    NeutriSci International is Canadian corporation that specializes in the marketing, development and distribution of proprietary nutraceuticals. It’s got a rather wide array of products in its portfolio, but the one of immediate interest is its pterostilbene, as it fits best with the hemp-absorption technology Lexaria Bioscience brings to the table.

    Pterostilbene (found in blueberries, by the way) is o

  • [By Matthew Briar]

    Indeed, it’s also garnered interest from business partners. In November, Lexaria Bioscience and NeutriSci International Inc (CVE:NU) jointly announced they were entering a joint venture that would utilize Lexaria Bioscience’s proprietary infusion platform and tap into NeutriSci International’s existing distribution network to create and market a whole new supplement product line. In January, the duo announced it had finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

  • [By Bryan Murphy]

    In the grand scheme of things it shouldn’t be surprising, though odds are good at least a few people are surprised at how quickly it happened. That is, health supplement and healthy-foods brand name NeutriSci International Inc (CVE:NU) and the developer of a cannabis-infusion technology — a means of packing more CBD into hemp oil — called Lexaria Bioscience Corp (OTCMKTS:LXRP) have finalized new supplement that is done testing and will soon be available for consumers. The tablet (a ‘melt’, technically) is a combination of pterostilbene and cannabidiol, offering a double-barreled benefit to the health-conscious.

    The benefits of cannabidiol, found in hemp and marijuana, are relatively well understood by the market at this point. Cannabidiol can do a human body a lot of good, like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more. Pterostilbene is the lesser-known of the two components of the new tablet, but no less impressive and no less beneficial. Pterostilbene is known to combat high cholesterol, high blood pressure, and oxidative stress. Combining the two is a real one-two punch for the health-conscious.

    That’s what made November’s news so exciting… NeutriSci International has an established name and marketing channel, while Lexaria Bioscience has the science that makes hemp oil far more functional. Indeed, to fully appreciate the upside for LXRP, one has to embrace Lexaria’s science and why it matters.

    The bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short,

  • [By Matthew Briar]

    Last week — to the day, in fact — Lexaria Bioscience Corp (OTCMKTS:LXRP) announced it was teaming up with neutraceutical company NeutriSci International Inc (CVE:NU) to create a new kind of health supplement that gave consumers the ability to tap into the benefits of hemp. We hailed it as the shape of things to come. What we didn’t know, however, was how quickly those things would take shape. Just this morning the company told LXRP shareholders it was already forging another such symbiotic relationship…. this one with Hempco Food and Fiber Inc (CVE:HEMP).

    Simply put, Lexaria Bioscience is focused on improving the bioavailability of the healthy stuff found in food, supplements, vitamins, and yes, even in cannabis and hemp.

    It’s not widely recognized, but the bulk of the vitamins, anti-oxidants, minerals, amino acids and all the other desirable components of the pills you take and foods you eat don’t actually get absorbed into your body. Sometimes as much as 96% of the ingredient in question isn’t extracted, and instead passes right through. Not only is it a waste of time and money, it’s a bit of a hassle to swallow a big capsule — or several capsules — for little to no benefit.

    Lexaria Bioscience changes this. In short, Lexaria has developed and patented a proprietary technology that makes valuable molecules taste better and absorb better in the digestive tract. This platform could be applied to a variety of nutritional and health-oriented favorites, but Lexaria is starting with hemp as it’s the most underserved market and arguably the biggest growth opportunity. Hemp, and hemp oil to be exact, can provide a lot of various medical benefits like the reduction of nausea, control of seizures, anti-cancer activity, anti-inflammation effects, and more.

    The future for Lexaria Bioscience is partnerships… licensing its science and know-how to companies with existing product lines and distribution networks that can easily inject hemp